Adage Capital Partners Gp, L.L.C. Allakos Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

  • $54.6 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$1.72 - $3.18 $430,172 - $795,318
250,100 New
250,100 $682,000
Q2 2023

Aug 14, 2023
SELL
$3.6 - $5.25 $178,257 - $259,959
-49,516 Reduced 28.17%
126,239 $550,000
Q1 2023

May 15, 2023
BUY
$4.3 - $8.27 $755,746 - $1.45 Million
175,755 New
175,755 $782,000

Others Institutions Holding ALLK

# of Institutions
81
Shares Held
64.7M
Call Options Held
47.1K
Put Options Held
1K
View Full List

About Allakos Inc.

ALLK Quotes by TradingView
  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $89.8M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email